Background and Purpose-To investigate whether molecular markers of inflammation and endothelial injury are associated with early growth of intracerebral hemorrhage (ICH). Methods-In a multicenter prospective study, we determined concentrations of interleukin-6 (IL-6), tumor necrosis factor-␣ (TNF-␣), matrix metalloproteinase-9 (MMP-9), and cellular fibronectin (c-Fn) in blood samples obtained on admission from 183 patients with primary hemispheric ICH of Ͻ12 hours' duration. Patients had a neurological evaluation and a computed tomography (CT) scan performed at baseline and at 48Ϯ6 hours. Early growth of the ICH was defined as a volume increase Ͼ33% between the 2 CT examinations for ICH with a baseline volume Ͻ20 mL and Ͼ10% for ICH Ն20 mL. Clinical, radiological, and biochemical predictive factors of ICH enlargement were analyzed by logistic regression analysis. Results-Fifty-four (29.5%) patients showed a relevant early growth of ICH. High leukocyte count and fibrinogen levels, low platelet count, and intraventricular bleeding were associated with early ICH growth in bivariate analyses.
PURPOSE To compare the late complications in the Ahmed Baerveldt Comparison Study during 5 years of follow-up. DESIGN Multicenter, prospective, randomized clinical trial. METHODS SETTINGS Sixteen international clinical centers. STUDY POPULATION Two hundred seventy six subjects aged 18 to 85 years with previous intraocular surgery or refractory glaucoma with intraocular pressure of > 18 mmHg. INTERVENTIONS Ahmed Glaucoma Valve FP7 or Baerveldt Glaucoma Implant BG 101-350. MAIN OUTCOME MEASURES Late postoperative complications (beyond 3 months), reoperations for complications, and decreased vision from complications. RESULTS Late complications developed in 56 subjects (46.8 ± 4.8 5 year cumulative % ± SE) in the Ahmed Glaucoma Valve group and 67 (56.3 ± 4.7 5 year cumulative % ± SE) in the Baerveldt Glaucoma Implant group (P = 0.082). The cumulative rates of serious complications were 15.9% and 24.7% in the Ahmed Glaucoma Valve and Baerveldt Glaucoma Implant groups respectively (P = 0.034) although this was largely driven by subjects who had tube occlusions in the two groups (0.8% in the Ahmed Glaucoma Valve group and 5.7% in the Baerveldt Glaucoma Implant group, P = 0.037). Both groups had a relatively high incidence of persistent diplopia (12%) and corneal edema (20%), although half of the corneal edema cases were likely due to pre-existing causes other than the aqueous shunt. The incidence of tube erosion was 1% and 3% in the Ahmed Glaucoma Valve and Baerveldt Glaucoma Implant groups, respectively (P = 0.04). CONCLUSIONS Long term rates of vision threatening complications and complications resulting in reoperation were higher in the Baerveldt Glaucoma Implant than the Ahmed Glaucoma Valve group over 5 years of follow-up.
Background and Purpose-Iron plays a detrimental role after experimental intracerebral hemorrhage (ICH). This study investigates whether high-serum ferritin levels are associated with poor outcome in patients with ICH. Methods-We studied 92 consecutive patients with primary hemispheric ICH within the first 12 hours from onset of symptoms (median, 3.3 hours). National Institute of Health Stroke Scale score, ICH, and peripheral edema volumes were measured at admission, 72 hours, and 7 days. Serum levels of ferritin and biomarkers of the inflammatory response were determined. The adjusted effect of ferritin on the full range of Rankin scale was analyzed by a general linear model. Results-Fifty-one patients (55.4%) had poor outcome (Rankin score Ͼ2). Older age, higher stroke severity, larger hematoma volume, intraventricular extension, mass effect, and higher IL-6 and ferritin levels at baseline (270. ron has been involved in cerebral injury after intracerebral hemorrhage (ICH) in experimental studies. Free iron released after erythrocyte lyses and from ferritin stores may have a role in oxidative stress, glutamate release, and inflammatory response after a hemorrhagic brain injury. 1-3 Iron chelators like deferoxamine can reduce brain edema and improve neurological function in experimental models of ICH. 4 Few data exist about clinical evidence of iron toxicity in ICH patients. 5 We collected our data with the objective to test if serum ferritin levels are associated with poor outcome in patients with ICH. Subjects and MethodsWe prospectively evaluated 100 consecutive patients with a primary supratentorial ICH admitted within the first 12 hours from onset of symptoms in 3 hospitals during 1 year. Exclusion criteria were previous disability, severe alcohol consumption, inflammatory or infectious liver, renal, hematologic diseases or cancer, secondary intracerebral hemorrhage, and coma. We further excluded 3 patients lost to follow-up and 5 patients in whom admission cranial CT was not available for volume calculations. The study was approved by the ethics committees of the participating centers and informed consent was signed by patients or their relatives. All patients were admitted at an acute stroke unit and treated according to the guidelines of the European Stroke Initiative. 6 Stroke severity was quantified using the National Institute of Health Stroke Scale score. Functional outcome was evaluated at 3 months using the modified Rankin scale, and poor outcome was defined as modified Rankin scale score Ͼ2.Cranial CT was performed at admission, 72 hours, and 7 days. ICH and peripheral hypodensity volume were measured using the formula of the ellipsoid, and edema volume was calculated by subtracting the volume of the ICH from that of the total lesion. Mass effect was considered when ventricular asymmetry or shifting of the midline structures was observed. All CT scans were centrally evaluated by an investigator who was masked to clinical data. ICH and edema growth ratios were calculated as: final volumeϪinitial vo...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.